PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Odronextamab→

Odronextamab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1801338-64-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Bispecific monoclonal antibodyCD20×CD3 T-cell-engaging immunotherapy
Mechanism of action
Binds CD20 on B-lineage cells and CD3 on T cells, bringing T cells into close proximity with malignant B cells and promoting T-cell-mediated cytotoxicity against CD20-expressing cells.
Indications / reported uses
  • Investigational treatment studied in adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma; this is not a statement of a universal marketing authorisation.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/odronextamab

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Odronextamab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Odronextamab Permitted Daily Exposure (PDE) report (the Odronextamab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Odronextamab Occupational Exposure Limit (OEL) report (the Odronextamab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.